The 3-year axillary RFS rate was 99.2% with axillary lymph node dissection and 98.8% with less-invasive procedures. Less-invasive lymph node procedures are noninferior to axillary lymph node ...

Dr. Rita Mukhtar and Dr. Joshua K. Sabari discuss the role of ctDNA to guide surgical decision-making after neoadjuvant chemo in breast cancer treatment. Dr. Rita Mukhtar and Dr. Joshua K. Sabari sat ...

Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: A systematic review and meta-analysis. This ...

Patients with initial nodal metastases and breast pCR on vacuum-assisted biopsy who underwent targeted axillary dissection had axillary pCR. HealthDay News — Omission of breast surgery after ...

Sentinel lymph node biopsy has replaced traditional axillary dissection, minimizing lymphedema risk in breast cancer surgery. The procedure targets the first draining lymph nodes, reducing unnecessary ...

Phase II study of neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant stage III triple negative breast ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...